The application for the first clinical trial with Talineuren, InnoMedica's drug in the field of neurology, for use in Parkinson's patients was submitted to Swissmedic. In March 2021, the versatile drug had also received orphan drug designation from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for use in the rare and incurable disease amyotrophic lateral sclerosis (ALS). A study for ALS patients will be submitted as soon as possible, once the first Parkinson's patients have been treated with Talineuren and the treatment dose has been determined.

The preclinical data on ALS were gathered together with the research group of Prof. Dr. Smita Saxena from the University of Bern and Inselspital, who accompanied the development of Talineuren for use in this severe disease from the very beginning - an extremely motivating project for the research group, which has achieved promising, positive results for ALS therapy.

Meet Prof. Dr. Saxena in a short interview conducted by Dr. Camille Peitsch, Manager Research & Development at InnoMedica, and learn more about the next steps in ALS research and what the use of Talineuren could mean for ALS patients.